Your browser doesn't support javascript.
Neurological Manifestations in COVID-19 Patients: A Meta-Analysis.
D, Vitalakumar; Sharma, Ankita; Kumar, Anoop; Flora, S J S.
  • D V; Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER)-Raeberali, Lucknow 226002, India.
  • Sharma A; Department of Biotechnology, National Institute of Pharmaceutical Education and Research (NIPER)-Raeberali, Lucknow 226002, India.
  • Kumar A; Department of Pharmacology and Clinical Research, Delhi Institute of Pharmaceutical Sciences and Research (DIPSAR), Delhi Pharmaceutical Sciences & Research University (DPSRU), New Delhi 110017, India.
  • Flora SJS; Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER)-Raeberali, Lucknow 226002, India.
ACS Chem Neurosci ; 12(15): 2776-2797, 2021 08 04.
Article in English | MEDLINE | ID: covidwho-1309426
ABSTRACT
Common symptoms such as dizziness, headache, olfactory dysfunction, nausea, vomiting, etc. in COVID-19 patients have indicated the involvement of the nervous system. However, the exact association of the nervous system with COVID-19 infection is still unclear. Thus, we have conducted a meta-analysis of clinical studies associated with neurological problems in COVID-19 patients. We have searched for electronic databases with MeSH terms, and the studies for analysis were selected based on inclusion and exclusion criteria and quality assessment. The Stats Direct (version 3) was used for the analysis. The pooled prevalence with 95% confidence interval of various neurological manifestations reported in the COVID-19 patients was found to be headache 14.6% (12.2-17.2), fatigue 33.6% (29.5-37.8), olfactory dysfunction 26.4% (21.8-31.3), gustatory dysfunction 27.2% (22.3-32.3), vomiting 6.7% (5.5-8.0), nausea 9.8% (8.1-11.7), dizziness 6.7% (4.7-9.1), myalgia 21.4% (18.8-24.1), seizure 4.05% (2.5-5.8), cerebrovascular diseases 9.9% (6.8-13.4), sleep disorders 14.9% (1.9-36.8), altered mental status 17.1% (12.3-22.5), neuralgia 2.4% (0.8-4.7), arthralgia 19.9% (15.3-25.0), encephalopathy 23.5% (14.3-34.1), encephalitis 0.6% (0.2-1.3), malaise 38.3% (24.7-52.9), confusion 14.2% (6.9-23.5), movement disorders 5.2% (1.7-10.4), and Guillain-Barre syndrome 6.9% (2.3-13.7). However, the heterogeneity among studies was found to be high. Various neurological manifestations related to the central nervous system (CNS) and peripheral nervous system (PNS) are associated with COVID-19 patients.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Guillain-Barre Syndrome / Encephalitis / COVID-19 / Nervous System Diseases Type of study: Observational study / Prognostic study / Reviews Limits: Humans Language: English Journal: ACS Chem Neurosci Year: 2021 Document Type: Article Affiliation country: Acschemneuro.1c00353

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Guillain-Barre Syndrome / Encephalitis / COVID-19 / Nervous System Diseases Type of study: Observational study / Prognostic study / Reviews Limits: Humans Language: English Journal: ACS Chem Neurosci Year: 2021 Document Type: Article Affiliation country: Acschemneuro.1c00353